Previous data suggest that persistent back pain may be associated with genetic variability. In this study, we assessed the correlation between 8 genetic polymorphisms (VDR, COL11, MMP1, MMP9, IL-1a, IL-1RN, OPRM1, COMT) and pain recovery in patients with low back pain (LBP) and lumbar radicular pain (LRP). In total, 296 patients with LBP or LRP were followed for 5 years. The patients underwent standardized clinical examination and completed pain and function questionnaires. Univariate linear regression associations with P values ,0.1 were included in the multivariable analysis, adjusting for pain intensity at baseline, age, sex, smoking, body mass index, and LBP or LRP. Pain intensity at 5-year follow-up was associated with VDR rs731236 (B 5 20.5, 95% confidence interval [CI] 20.9 to 20.1, P 5 0.017), MMP9 rs17576 (B 5 0.5, 95% CI 0.1-0.9, P 5 0.022), and OPRM1 rs1799971 (B 5 20.8, 95% CI 21.4 to 20.2, P 5 0.006) in the univariate analyses. MMP9 rs17576 and OPRM1 rs1799971 remained significant (B 5 0.4, 95% CI 0.05-0.8, P 5 0.026 and B 5 20.8, 95% CI 21.3 to 20.2, P 5 0.007) in the multivariable model. Thus, the data demonstrated that the rare allele of MMP9 rs17576 was associated with poor pain recovery, whereas the rare allele of OPRM1 rs1799971 was associated with better pain recovery at 5-year follow-up in the LBP and LRP patients. In particular, the present study suggested that the OPRM1 rs179971 A.G in men was associated with better long-term pain recovery. In men, the OPRM1 rs1799971 explained 4.7% of the variance of pain intensity. We conclude that the MMP9 rs17576 and OPRM1 rs1799971 genotypes may affect 5-year recovery in patients with LBP and LRP.
Introduction
Previous data show that low back pain (LBP) has a lifetime prevalence of 70%. 2 Lumbar radicular pain (LRP), also referred to as "sciatica," accounts for only 5% to 10% of these LBP conditions. Although most back disorders are benign, many have a slow recovery. 12, 38 In regard to LBP, this condition may have a muscular aetiology. 27 However, back disorders can also be related to degenerative changes in the intervertebral disks or in the spine. If such changes cause mechanical compression of the nerve roots, this may lead to LRP. In addition, biochemical mediators released after disk herniation may influence neuronal excitability and promote pain. 34 LBP and LRP are multifactorial phenomena. Age, smoking, body weight, height, occupational load, mental stress, and perceptual processes may all contribute to development of persistent LBP and LRP. 3, 16, 22, 37, 39 Moreover, genetic variability that influences susceptibility to environmental factors may influence the risk of chronic pain. 1, 31 Earlier data suggest that the heritability of back pain ranges from 30% to 45%. 36 Several lines of evidence show that genetic factors, which are important for degenerative changes, inflammation, and pain perception, also play a role in LBP conditions.
For example, genetic variants in genes encoding proteins such as vitamin D receptor (VDR), collagens (COL), and matrix metalloproteinases (MMPs) may affect degeneration of the intervertebral disks. 9, 35 Previous studies indicate that genetic polymorphisms related to inflammation in genes encoding interleukin-1 (IL-1a), interleukin-1 receptor antagonist (IL-1RN), and interleukin-6 may also promote persistent LRP. 15, 23, 26, 32 Moreover, genetic variability that is important for opioid, dopaminergic, adrenergic, and serotonergic signalling may affect supraspinal modulation of nociceptive processing. [40] [41] [42] Several previous studies demonstrate a link between genetic variability in the gene encoding opioid receptor mu 1 (OPRM1) and pain recovery in LRP patients. 13, 28 In addition, genetic variability related to the enzyme catechol-Omethyltransferase (COMT) may affect pain processing and the risk of long-lasting pain conditions. 7, 8, 24 Hence, several genetic variants have been suggested to be of importance for persistent LBP and LRP. To our knowledge, this is the first study addressing the link between genetic factors and pain recovery over a 5-year period. The aim of the present study was to test a panel of genetic variants, namely VDR rs731236, COL11 rs1676486, MMP1 rs1792750, MMP9 rs17576, IL-1a rs1800587, IL-1RN rs2234677, OPRM1 rs1799971, and the COMT rs6269/ rs4633/rs4818/rs4680 haplotype regarding pain recovery in LRP and LBP patients. The present data suggest that genetic factors may predict the long-term recovery in patients with LBP and LRP. The inclusion criteria for the LRP patient were age between 18 and 60 years, lumbar disk herniation on magnetic resonance imaging (MRI) with corresponding distribution of pain in lower limbs and positive straight leg raising test. The exclusion criteria were cauda equina syndrome, lumbar spinal stenosis, previous spinal surgery for a herniated disk at the same level or lumbar fusion at any level, generalized musculoskeletal pain, inflammatory rheumatic disease, diabetic polyneuropathy, cardiovascular disease (NYHA class III and IV), cancer, psychiatric disease, drug misuse and alcoholism, recent surgery (within 1 month), pregnancy, poor proficiency in the Norwegian language and non-European-Caucasian ethnicity. In total, 270 LRP patients were included and followed over 5 years. The dropout rate in the first year was 9%. Two hundred fifty-one LRP patients were allocated to 5-year follow-up with a response rate of 76% (Fig. 1) .
Methods

Study population
The inclusion criteria for the LBP patients were age between 18 and 65 years and persisting LBP. The exclusion criteria were lumbar disk herniation on MRI with corresponding distribution of pain in lower limbs, positive Laseque, cauda equina syndrome, lumbar spinal stenosis, structural deformity of the vertebral column, previous surgery on the back, generalized muscular and skeletal pain, inflammatory rheumatic diseases, diabetic mellitus with polyneuropathy, comprehensive cardiac disease, cancer, or other serious diseases. In total, 148 LBP patients were included and followed up with at 4 months and 1 year. The dropout rate in the first year was 7%. One hundred thirty-six LBP patients were allocated to 5-year follow-up with a response rate of 78% (Fig. 1) .
The study was conducted in accordance with the Helsinki Declaration. The Regional Committee for Medical Research Ethics (reference number 2014/1754) and the Norwegian Social Science Data Service approved the study protocol and all the participants gave their written informed consent at baseline and at 5-year follow-up.
Clinical procedures and outcome measures
All patients underwent a standardized clinical examination, which included assessment of sensory and motor functions including straight leg raising and completion of standardized pain and function questionnaires. At baseline, sociodemographic variables, including sex, age, smoking habits, and body mass index (BMI) were registered and baseline MRI obtained for all patients.
Pain intensity was recorded using the visual analogue scale (VAS) with anchor values from 0 (no pain) to 10 (worst possible pain) at rest during the last week at baseline and at 5-year followup. 33 In addition, function was assessed using the validated Norwegian version of the Oswestry Disability Index (ODI), scale 0% to 100%, where 0% 5 no disability at all and 100% 5 very severe disability at baseline and 5-year follow-up. 11 
Genotyping
In patients with LRP, genomic DNA was extracted from whole blood cells using a FlexiGene DNA isolation kit (Qiagen), whereas in patients with LBP, genomic DNA was extracted from saliva using an Oragene DNA sample collection kit (DNA Genotech Inc., Foster City, CA) according to the manufacturer's instructions. Table 1 The genetic variants tested.
Gene rs number Base substitution Amino acid substitution
The rs number (reference SNP cluster ID) refers to the specific SNP, created by the National Center for Biotechnology Information (NCBI Single-nucleotide polymorphism (SNP) genotyping was carried out using predesigned TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA). Approximately 10 ng DNA was amplified in a 5 mL reaction mixture in a 384-well plate containing 13 universal TaqMan Master Mix and 13 assay mix; the latter containing the respective primers and probes. The probes were labeled with the reporter dyes FAM or VIC at the 5' end to distinguish between the 2 alleles. The reactions were performed on an ABI 7900HT sequence detection system (Applied Biosystems) using the following program: 95˚C for 10 minutes, followed by 40 cycles at 95˚C for 15 seconds and 60˚C for 1 minute. Negative controls containing water instead of DNA were included in every run. Genotypes were determined using SDS 2.2 software (Applied Biosystems). Phase v.2.1.1 was used to define the COMT haplotypes. Approximately 10% of the samples were regenotyped, and the concordance rate was 100%. The SNPs tested are listed in Table 1 .
Statistical analysis
An univariate linear regression analysis was first performed to estimate the correlation between the 8 genetic variants (VDR, COL11, MMP1, MMP9, IL-1a, IL-1RN, OPRM1, COMT) and pain (VAS) or disability (ODI score) at 5-year follow-up.
Potential confounding effects of the covariates baseline pain, LRP/LBP, age, sex, smoking (yes/no), and BMI were included in the models.
To keep all genetic factors and covariates potentially contributing, factors with P , 0.1 were entered in the multivariate linear regression models. The conventional P , 0.05 was applied to evaluate the relationship between the genetic variability and pain recovery or disability in the final model. Regarding the OPRM1 variant, additional univariate and multivariable linear regression analyses separately in women and men were performed.
All models were checked for collinearity (no collinearity revealed). An allele-dependent model was assumed, such that the effect of the genotype rare/rare was expected to be twice the effect of the genotype rare/common when compared to the genotype common/common. All the statistical analyses were performed using the SPSS (version 22) statistical package. A P value ,0.05 was set as the level of statistical significance.
Results
Characteristics of study population
The study population comprised 296 patients, including 128 females (43.2%) and 168 males (56.8%), aged 18 to 60 years (mean 42.1 6 9.9 years). At baseline, 99 patients (33.4%) smoked on a daily basis ( Table 2) . At 5-year follow-up, the LBP patients reported more pain (3.7 6 2.9) than the LRP patients (2 6 2.1). The LBP patients also reported worse function (ODI 28.2 6 14.3) than the LRP patients (ODI 15.53 6 14.8).
Genetic predictors
A significant association between pain intensity at rest at 5-year follow-up (VAS rest 5 years) and the VDR rs731236 (P 5 0.017) SNP, the MMP9 rs17576 (P 5 0.022) SNP, and the OPRM1 rs1799971 SNP (P 5 0.006) was found. In the multivariable models adjusted for pain intensity at baseline, LRP or LBP, sex, age, smoking, and BMI, only the MMP9 rs17576 SNP and the OPRM1 rs1799971 SNP showed correlation with P , 0.1 and were kept in further analysis ( Table 3) . Pain location (LRP or LBP) had a large impact on the results of multivariable regression analyses, as did the covariate pain at rest baseline (P , 0.001, P , 0.001). In the final model with the MMP9 rs17576 SNP and the OPRM1 rs1799971 SNP, corrected for pain intensity baseline and LRP/LBP, each gene showed an independent contribution to pain recovery (P 5 0.026, P 5 0.007) ( Table 3 ). In accordance with our hypothesis, presence of the rare allele of the MMP9 rs17576 SNP was associated with poor pain recovery. However, patients with the rare allele of the OPRM1 rs1799971 SNP in men reported better pain recovery ( Table 4 ). The MMP9 rs17576 SNP explained 1.8% (R 2 5 0.018) and the OPRM1 rs1799971 SNP explained 2.5% (R 2 5 0.025) of the variance in pain intensity at 5 years. OPRM1 rs179971 explained 4.7% (R 2 5 0.047) of the pain intensity in men.
A significant association between disability at 5-year follow-up (ODI 5 year) and the VDR rs731236 SNP was found (P 5 0.017), but in the multivariate models adjusted for disability at baseline, LRP or LBP, sex, age, smoking, and BMI, this association did not remain significant (data not shown).
Discussion
Many studies have shown that lumbar disk degeneration is associated with LBP and LRP. 4, 5, 36 Previous data also suggest that genetic markers may be linked to the same degenerative disk phenomenon. 9, 36 For example, 2 independent Japanese cohorts show that the MMP9 rs17576 A.G is associated with lumbar disk herniation. 9, 14 In line with these findings, our data showed that the MMP9 rs17576 A.G, previously linked to tissue degeneration, was associated with slow recovery.
Earlier data also suggest that the MMP1 rs1799750 1 G.2 G may be associated with painful degenerative conditions. 6, 29 Moreover, the COL11 rs1676486 G.A has previously been linked to increased risk for LRP, 21, 25 whereas the VDR rs731236 T.C may be associated with disk degeneration. 9, 35 In addition, several lines of evidence suggest that genetic variability in genes encoding inflammatory cytokines may be associated with persistent back pain. 18, 36 For example, the IL-1a rs1800587 C.T may be associated with more pain at 1 year in LRP patients. 23, 32 However, no relationship between genetic variability in these genes and pain recovery was observed in our study.
OPRM1 may be crucial for sensory processing and modulation of back pain and other pain conditions. Two previous studies that emanate from our LRP cohort reported a positive association between the OPRM1 rs179971 A.G and better recovery of pain in men at 1-year follow-up. 13, 28 Moreover, earlier observations show that the OPRM1 rs1799971 A.G may be associated with higher pressure pain thresholds 10 and lower cortical responses to experimental pain stimuli. 19 In accordance with these earlier observations, the present data suggest that the OPRM1 rs1799971 A.G in men is associated with better long-term pain recovery.
Like the OPRM1 genotype, the genetic variability related to the COMT enzyme may be important for pain. The COMT enzyme metabolizes catecholamines and thus modulates adrenergic, noradrenergic, and dopaminergic signaling in the central nervous system as well as in the peripheral tissue. Therefore, many supraspinal processes including nociceptive modulation may be affected by genetic factors that influence on the COMT enzyme. Previous data suggest that the COMT haplotype rs6269/rs4633/ rs4818/rs4680 ACCG may be associated with increased pain. 8, 24, 30 No relationship between the COMT rs6269/rs4633/ rs4818/rs4680 haplotype and pain recovery was, however, observed in this study.
In the present study, we did not check for psychosocial covariates, although psychosocial factors, such as anxiety, depression, and somatization, may contribute to chronic LBP and LRP. 20 Therefore, indirect effects of MMP9 rs17576 and OPRM1 rs1799971 on pain cannot be excluded. Still, together with individual factors such as sex, age, smoking, obesity, and education level, genetic predisposition may be a prognostic factor in LBP patients as well as LRP patients. 20, 22 Thus, development of persistent pain may be multifactorial. In contrast to earlier studies with shorter follow-up, 17 however, our LBP patients reported more pain than our LRP patients at 5-year follow-up. This emphasizes that the maintenance of persistent pain is also probably a dynamic process. The pain mechanisms at 1, 2, and 5 years may be different.
In summary, the present data demonstrated that the rare allele of MMP9 rs17576 was associated with poor pain recovery, whereas the rare allele of OPRM1 rs1799971 was associated with better pain recovery in LBP and LRP patients. Hence, although the causal relationship between these SNPs and the pain remains to be investigated, our results support the hypothesis that genetic factors involved in tissue degeneration and pain perception may predict long-term recovery in these patients. However, each SNP explained only about 2% to 5% of the variance, emphasizing the multifactorial nature of LBP and LRP. 
